Bioventus
BVS
69 hedge funds and large institutions have $352M invested in Bioventus in 2021 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 30 increasing their positions, 14 reducing their positions, and 7 closing their positions.
229% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 7
114% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 14
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
30% more funds holding
Funds holding: 53 → 69 (+16)
10.04% more ownership
Funds ownership: 50.48% → 60.51% (+10%)
3% less capital invested
Capital invested by funds: $364M → $352M (-$12.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$41.2M |
| 2 |
JIC
Juniper Investment Company
New York
|
+$9.28M |
| 3 |
NI
Nuance Investments
Kansas City,
Missouri
|
+$7M |
| 4 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$5.71M |
| 5 |
BlackRock
New York
|
+$4.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$13.7M |
| 2 |
Millennium Management
New York
|
-$3.11M |
| 3 |
PP
Prospector Partners
Guilford,
Connecticut
|
-$2.19M |
| 4 |
PVI
Pura Vida Investments
New York
|
-$1.78M |
| 5 |
Renaissance Technologies
New York
|
-$956K |
BVS Hedge Fund Activity: Q3 2021 in Review
69 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Bioventus (BVS) for Q3 2021, worth a combined $352M — down 3.5% from $364M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new BVS positions and 7 closed out — a net gain of 16 holders — while 30 added to existing stakes and 14 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $41.2M. The largest seller was Deerfield Management, exiting entirely with an estimated $13.7M sold.
- 69 institutional investors held Bioventus (BVS) as of Q3 2021, up from 53 in Q2 2021.
- Funds reported $352M of Bioventus stock for Q3 2021, down 3.5% quarter-over-quarter.
- 23 funds opened new Bioventus positions in Q3 2021 and 7 closed out, a net change of +16 holders.
- The largest Bioventus buyer in Q3 2021 was T. Rowe Price Associates, an estimated $41.2M added.
- The largest Bioventus seller in Q3 2021 was Deerfield Management, an estimated $13.7M sold.
Based on aggregated 13F filings for Q3 2021.